About

Dr. Tahmid Rahman, MD, is a Clinical Assistant Professor of Medicine in the division of Cardiology at Stony Brook Medicine. His clinical practice focuses on noninvasive cardiology and clinical lipidology, with expertise in managing cholesterol disorders including familial hypercholesterolemia and atherosclerotic heart disease. He is the Associate Director for Quality and Performance in Cardiology and the Associate Director for the Center for Advanced Lipid Management. Dr. Rahman is board certified in clinical cardiology, internal medicine, echocardiography, nuclear cardiology, and clinical lipidology. His research is centered on cholesterol management, including involvement in clinical trials for novel medications such as inclisiran, and he is engaged in quality improvement initiatives within the cardiovascular department. He completed his fellowship in cardiology at Stony Brook University Hospital and has remained on faculty to provide patient care, education, and mentorship to students, residents, and fellows. Raised in Elmont, NY, Dr. Rahman is dedicated to improving cardiovascular health in his Long Island community and aims to reach out to the growing South Asian population in Suffolk County to treat and educate this group, which is known to have a higher risk of heart disease.

Research topics

• Cardiology
• Medicine
• Internal medicine
• Radiology
• Surgery
• Intensive care medicine
• Anesthesia

Selected publications

• UTILITY OF INTRAAORTIC BALLOON COUNTERPULSATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK

  Journal of the American College of Cardiology · 2025-03-29

  articleOpen access
  PublisherDOI

• A CURIOUS CASE OF HFPEF

  Journal of the American College of Cardiology · 2025-03-30

  articleOpen accessSenior author
  PublisherDOI

• Lipoprotein(a) as a Predictor of Cardiovascular Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review

  Reviews in Cardiovascular Medicine · 2025-09-22 · 1 citations

  reviewOpen access

  Background: Despite advancements in treatment, coronary artery disease (CAD) remains a significant global health concern. Although lipoprotein(a) [Lp(a)] is recognized as a crucial cardiovascular risk factor associated with increased risk, the prognostic value of using Lp(a) levels in patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI) remains debatable. This review aimed to investigate the association between Lp(a) levels and recurrent ischemic events in patients with ACS undergoing PCI. Methods: This systematic review included studies with individuals aged ≥18 years diagnosed with ACS who underwent PCI and had Lp(a) measurements. The included studies were sourced from the PubMed database, with a focus on articles published between January 2020 and January 2025. Keywords related to Lp(a) and cardiovascular diseases were used in the search. Data extraction involved a review of titles and abstracts followed by quality assessment using the QUADAS-2 tool. Results: The final analysis included 10 studies with a combined population of 20,896 patients from diverse regions, including Japan, India, Egypt, China, and South Korea. Key findings indicate that elevated Lp(a) levels are significantly associated with adverse cardiovascular outcomes, including myocardial infarction and mortality, both in hospital and during long-term follow-up. Conclusions: This review highlights Lp(a) as a critical biomarker for predicting recurrent cardiovascular events in ACS patients post-PCI. The consistent correlation between elevated Lp(a) levels and adverse outcomes underscores the necessity of routine monitoring and targeted management of Lp(a) to mitigate residual cardiovascular risk.

  PublisherOA PDFDOI

• A Case of Familial Hypoalphalipoproteinemia with Significant Premature Atherosclerosis

  Journal of clinical lipidology · 2024-07-01

  article1st authorCorresponding
  PublisherDOI

• Primary Hypoalphalipoproteinemia With Significant Premature Atherosclerosis

  JACC Case Reports · 2024-12-01

  articleOpen accessSenior author

  Primary hypoalphalipoproteinemia is typically caused by genetic disorders and is characterized by low high-density-lipoprotein cholesterol (HDL-C). Low HDL-C has been proposed to confer an increased risk of atherosclerotic cardiovascular disease; however, a causal relationship has not been determined. We describe the case of an otherwise healthy and asymptomatic 37-year-old woman with severely low HDL-C who was found to have significant coronary artery disease in whom genetic testing supported a diagnosis of Tangier disease. Current lipid management guidelines focus on optimization of total cholesterol and low-density-lipoprotein cholesterol (LDL-C), although the lipid profile of patients with primary hypoalphalipoproteinemia typically portrays favorable non-HDL levels. Clinical trials investigating medications that target low HDL-C have failed to show a clear benefit in cardiovascular outcomes. Based on current evidence, patients with genetic disorders that manifest through low HDL-C and optimal LDL-C should be managed with lifestyle modification and statin therapy.

  PublisherDOI

• †The Role of Structured Inpatient Lipid Protocols in Optimizing Non-Statin Lipid Lowering Therapy: A Review and Single-Center Experience

  Journal of clinical lipidology · 2024-07-01

  reviewSenior author
  PublisherDOI

• The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience

  Frontiers in Cardiovascular Medicine · 2024-01-25 · 4 citations

  reviewOpen access

  Dyslipidemia is a leading contributor to atherosclerotic cardiovascular disease (ASCVD). There has been a significant improvement in the treatment of dyslipidemia in the past 10 years with the development of new pharmacotherapies. The intent of this review is help enhance clinicians understanding of non-statin lipid lowering therapies in accordance with the 2022 American College of Cardiology Expert Consensus Clinical Decision Pathway on the Role of Non-statin Therapies for LDL-Cholesterol Lowering. We also present a single-center experience implementing a systematic inpatient protocol for lipid lowering therapy for secondary prevention of ASCVD.

  PublisherOA PDFDOI

• SAFETY OF ANTI-HYPERTENSIVE MEDICATIONS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION

  Journal of the American College of Cardiology · 2024-04-01

  article
  PublisherDOI

• Utility of venoarterial extracorporeal membrane oxygenation in patients with acute myocardial infarction complicated by cardiogenic shock

  European Heart Journal · 2024

  • Medicine
  • Cardiology
  • Internal medicine

  Abstract Background Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) continues to portend poor clinical prognosis and remains a major cause of morbidity and mortality. Although venoarterial (VA) extracorporeal membrane oxygenation (ECMO) is frequently used in the treatment of AMI-CS, studies evaluating its benefit compared to percutaneous ventricular assist devices (pVAD) or standard medical therapy in this patient population have yielded conflicting results. Purpose The goal of this meta-analysis is to evaluate the use of ECMO compared to either pVAD or medical therapy with or without intra-aortic balloon counterpulsation (IABP) in patients presenting with AMI-CS. Methods A database search was performed for studies reporting on the association of ECMO compared to pVAD or medical therapy with or without IABP with clinical outcomes in patients with AMI-CS. The endpoints of interest were 30-day all-cause mortality and long term all-cause mortality. The databases searched included Pubmed, Web of Science, and Embase. The search was not restricted by time or publication status. Registry studies were excluded from this analysis. Results A total of 8 studies with 937 participants (447 treated with ECMO, 243 treated with pVAD, 247 treated with medical therapy with or without IABP) met inclusion criteria. Mean age was 63 years old, 80.5% were men, mean left ventricular ejection fraction was 26%, mean follow-up was 6.3 months (ranging 1-12 months). Treatment of AMI-CS patients with ECMO was not associated with lower risk of 30-day all-cause mortality compared to pVAD or standard medical therapy with or without IABP placement (OR 1.29, 95% CI 0.87-1.90; p=0.21; OR 0.58, 95% CI 0.25-1.35; p=0.13). Heterogenetic was low to moderate for each subgroup. Test for subgroup differences did not demonstrate statistically significant differences in the results for pVAD and for standard medical therapy with or without IABP (p=0.10, I2=64.1%). Compared to pVAD, ECMO was not associated lower risk of long-term mortality (OR 1.27, 95% CI 0.85-1.90; p=0.24). The heterogeneity for this analysis was low (I2=0%). Conclusion In patients presenting with AMI-CS, use of VA-ECMO is not associated with lower risk of mortality compared to pVAD or standard medical therapy with or without IABP placement. The risks and benefits of ECMO should be carefully considered compared to other forms of temporary mechanical circulatory support.Figure 1

  PublisherDOI

• Utility of native T1 mapping and myocardial extracellular volume fraction in patients with nonischemic dilated cardiomyopathy: A systematic review and meta-analysis

  IJC Heart & Vasculature · 2024 · 8 citations

  • Medicine
  • Internal medicine
  • Cardiology

  Background: -analysis aims to characterize the utility of native T1 mapping and ECV in patients with non-ischemic cardiomyopathy (NICM) and to clarify the prognostic significance of elevated values. Methods: A literature search was conducted for studies reporting on use of CMR-based native T1 mapping and ECV measurement in NICM patients and their association with major adverse cardiac events (MACE), ventricular arrhythmias (VAs), and left ventricular reverse remodeling (LVRR). Databases searched included: Ovid MEDLINE, EMBASE, Web of Science, and Google Scholar. The search was not restricted to time or publication status. Results: Native T1 and ECV were significantly higher in NICM patients compared to controls (MD 78.80, 95 % CI 50.00, 107.59; p < 0.01; MD 5.86, 95 % CI 4.55, 7.16; p < 0.01). NICM patients who experienced MACE had higher native T1 and ECV (MD 52.87, 95 % CI 26.59, 79.15; p < 0.01; MD 6.03, 95 % CI 3.79, 8.26; p < 0.01). There was a non-statistically significant trend toward higher native T1 time in NICM patients who experienced VAs. NICM patients who were poor treatment responders had higher baseline native T1 and ECV (MD 40.58, 95 % CI 12.90, 68.25; p < 0.01; MD 3.29, 95 % CI 2.25, 4.33; p < 0.01). Conclusions: CMR-based native T1 and ECV quantification may be useful tools for risk stratification of patients with NICM. They may provide additional diagnostic utility in combination with LGE, which poorly characterizes fibrosis in patients with diffuse myocardial involvement.

  PublisherDOI

Frequent coauthors

• Michael Tao

  Stony Brook University Hospital

  18 shared

• Noelle Mann

  13 shared

• Chad Gier

  Stony Brook University Hospital

  11 shared

• Simrat Dhaliwal

  Stony Brook University Hospital

  9 shared

• Travis Bench

  Stony Brook University Hospital

  7 shared

• Mohammed Al‐Sadawi

  Memorial Sloan Kettering Cancer Center

  6 shared

• T Figueira

  Stony Brook University Hospital

  5 shared

• Paola Pastena

  Stony Brook Medicine

  5 shared